In Vivo Efficacy of a Macrocyclic Peptoid‐Peptide Hybrid That Selectively Modulates the Beta‐Catenin/TCF Interaction to Inhibit Prostate Cancer
The Prostate · 2025
DOI: 10.1002/pros.24868 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Justine Habault und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: beta Catenin, Prostatic Neoplasms, Peptoids, TCF Transcription Factors. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R21CA262963 and R….
Abstract (Originalsprache)
Background
Prostate cancer is the most common form of male cancer and can initially be treated as a localized disease. Although the 5‐year survival rate at diagnosis approaches 100 percent, a subset of patients will subsequently develop resistance to treatment. This may ultimately lead to metastatic castration resistant prostate cancer (mCRPC), for which the prognosis is much less favorable. The importance of the Wnt/β‐catenin pathway in treatment‐resistant prostate cancer has inspired efforts to exploit the interaction of β‐catenin with its transcription binding partners as a therapeutic strategy for prostate cancer.
Methods
Peptoid‐peptide macrocycles are attractive design scaffolds for disrupting protein‐protein interactions. In this study, we evaluate a library of these macrocycles and demonstrate their selectivity for the β‐catenin/TCF ( T C ell F actor) interaction.
Results
Importantly, we show that the macrocycles do not significantly alter the binding of β‐catenin to cell surface protein, E‐cadherin. Our lead sequence, Macrocycle 13, (MC13) was also tolerant of modifications aimed to improve aqueous solubility while retaining activity. Herein, we demonstrate in vivo proof of principle for using peptidomimetic macrocycles to target the β‐catenin/TCF interaction. Treated prostate cancer mouse xenografts show markedly diminished tumor growth and decreased levels of myc protein. MC13 also inhibits growth in an organoid model with genetic alterations frequently found in prostate cancer. Transcriptome analysis of prostate cancer cells treated with MC13 reveals downregulation of key pathways, including Wnt/β‐catenin and c‐myc. Furthermore, chromatin immunoprecipitation (ChIP) analysis shows reduced β‐catenin at its target genes, axin2 and c‐myc.
Conclusion
Our findings underscore the therapeutic potential of peptoid‐peptide macrocycle inhibition of β‐catenin in prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA.
- Chemistry Department, New York University, New York, New York, USA.
- Department of Urology, NYU Grossman School of Medicine, New York, New York, USA.
- Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, New York, USA.
- Department of Medicine, Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, New York, USA.
ORCID-Profile: Susan K Logan
Förderung
- NCI NIH HHS
- Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R21CA262963 and R…
Zitieren
APA
Habault, J., Franco, J. L., Ha, S., Schneider, J. A., Voisin, M., Wise, D. R., Wong, K. K., Garabedian, M. J., Kirshenbaum, K., & Logan, S. K. (2025). In Vivo Efficacy of a Macrocyclic Peptoid‐Peptide Hybrid That Selectively Modulates the Beta‐Catenin/TCF Interaction to Inhibit Prostate Cancer. The Prostate. https://doi.org/10.1002/pros.24868
Vancouver
Habault J, Franco JL, Ha S, Schneider JA, Voisin M, Wise DR, et al. In Vivo Efficacy of a Macrocyclic Peptoid‐Peptide Hybrid That Selectively Modulates the Beta‐Catenin/TCF Interaction to Inhibit Prostate Cancer. The Prostate. 2025. doi:10.1002/pros.24868
BibTeX
@article{Habault2025,
author = {Habault, Justine and Franco, Jennifer L and Ha, Susan and Schneider, Jeffry A and Voisin, Maud and Wise, David R and Wong, Kwok-Kin and Garabedian, Michael J and Kirshenbaum, Kent and Logan, Susan K},
title = {In Vivo Efficacy of a Macrocyclic Peptoid‐Peptide Hybrid That Selectively Modulates the Beta‐Catenin/TCF Interaction to Inhibit Prostate Cancer},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24868}
}
EUVIMED